Fibocom Wireless Logs 92% Lower Profit in Q1 2026

Huadong Medicine Registers New Aesthetics Product Variant in China; Shares Jump 4%

Huadong Medicine (SHE:000963) has obtained a medical device registration certificate from China's National Medical Products Administration for a new variant of its Ellansé aesthetics product, according to a Shenzhen Stock Exchange filing on Friday.The newly approved Ellansé M-type is a Class III medical device for injection containing polycaprolactone microspheres for facial filling. It has been approved for market launch, said Huadong.The M-type variant is designed for the temporal region. Huadong has already been marketing its Ellansé S-type product in China since August 2021.Shares of the company rose 4% in recent trade.

Vinyl Group Revises Guidance to Expected EBITDA Positive Run-Rate in Fiscal 2027 H1, Shares Reach Two-Year Low

Vinyl Group (ASX:VNL) revised its guidance to an expected earnings before interest, taxes, depreciation, and amortization (EBITDA) positive run-rate in the first half of fiscal year 2027, with timing impacted by the delayed completion of Val Morgan Digital and the mergers and acquisitions pipeline, according to a Friday Australian bourse filing.It reported cash receipts of AU$4 million in the third quarter of fiscal 2026, up 24% on the prior corresponding period. The Platforms business was up 19% year-over-year, while the advertising market was relatively soft in the March quarter, per the filing.Its shares fell 6% in recent trading on Friday, reaching a two-year low.

Nomura Adjusts Hyundai Motor's Price Target to KRW640,000 from KRW650,000, Keeps at Buy